Roseola Infantum in Emergency Medicine
- Author: Lisa S Lewis, MD; Chief Editor: Kirsten A Bechtel, MD more...
Roseola infantum is the sixth of the traditional exanthems of childhood. The condition is an acute benign disease of childhood classically characterized by a history of a prodromal febrile illness lasting approximately 3 days, followed by defervescence and the appearance of a faint pink maculopapular rash.
Since identification of the etiologic agent human herpesvirus type 6 (HHV-6), infection has been documented without the characteristic fever or rash. The virus may present as an acute 3-7 day febrile illness (characteristically >39.5 º C) associated with respiratory or gastrointestinal symptomatology. In one prospective cohort, 93% of newly acquired infections were symptomatic, with fever, fussiness, diarrhea, and rash as the most distinguishing features.
Newly recognized clinical manifestations of HHV-6 infection include hepatitis, encephalitis, myocarditis, hemophagocytic syndrome, and an adult mononucleosislike illness. The virus persists and may reactivate, primarily in immunocompromised hosts. Reactivation manifestations may present as fever, rash, pneumonia, hepatitis, bone marrow suppression, and encephalitis. The full spectrum of clinical manifestations of HHV-6 has not been elucidated.
Respiratory secretions of asymptomatic individuals likely transmit the virus. The child is most likely to spread the infection during the febrile and viremic phase of the illness.
Cell-associated viremia has been noted, usually on the third day of illness and immediately before rash appearance. By the eighth day of illness, antibody activity peaks and results in resolution of the viremia.
Children with the cell-free virus also have been noted. This likely represents a greater magnitude of viral dissemination because these children have more severe clinical manifestations.
Approximately 12-30% of children have clinical manifestations consistent with roseola. Eighty-six percent of children have acquired HHV-6 antibodies by age 1 year. By age 4 years, almost all children are seropositive. Roseola appears to peak in spring and fall.
A relationship seems to exist among prevalence, geographic location, and ethnicity. The prevalence of roseola is 92% in Ecuador, 60% in Japan, 20% in Morocco, and 49-76% in Malaysia. The disease is more prevalent among younger infants in Japan than in the United States or Europe.
Roseola is usually a self-limited illness with no sequelae.
The major morbidity associated with roseola is seizures (6-15%) during the febrile phase of the illness.
Encephalitis, fulminant hepatitis, hemophagocytic syndrome, and disseminated infection with HHV-6 are extremely rare manifestations in healthy hosts. Immunosuppression secondary to transplantation may result in viral replication and reactivation. While HHV-6 is commonly detected post transplantation, it is generally asymptomatic. However, it has been implicated in encephalitis, hepatitis, bone marrow suppression, and pneumonitis in a minority of cases.
No predilection for roseola infantum exists.
Most cases present within the first 2 years of life, with peak occurrence in infants aged 9-21 months.
Zerr DM, Meier AS, Selke SS, Frenkel LM, Huang ML, Wald A. A population-based study of primary human herpesvirus 6 infection. N Engl J Med. 2005 Feb 24. 352(8):768-76. [Medline].
Dockrell DH, Paya CV. Human herpesvirus-6 and -7 in transplantation. Rev Med Virol. 2001 Jan-Feb. 11(1):23-36. [Medline].
Stoeckle M. The spectrum of human herpesvirus 6 infection: from roseola infantum to adult disease. Annu Rev Med. 2000. 51:423-430. [Medline].
Vianna RA, de Oliveira SA, Camacho LA, Knowles W, Brown D, Pereira AC, et al. Role of human herpesvirus 6 infection in young Brazilian children with rash illnesses. Pediatr Infect Dis J. 2008 Jun. 27(6):533-7. [Medline].
Tanaka-Taya K, Sashihara J, Kurahashi H, Amo K, Miyagawa H, Kondo K, et al. Human herpesvirus 6 (HHV-6) is transmitted from parent to child in an integrated form and characterization of cases with chromosomally integrated HHV-6 DNA. J Med Virol. 2004 Jul. 73(3):465-73. [Medline].
Boutolleau D, Duros C, Bonnafous P, Caiola D, Karras A, Castro ND, et al. Identification of human herpesvirus 6 variants A and B by primer-specific real-time PCR may help to revisit their respective role in pathology. J Clin Virol. 2006 Mar. 35(3):257-63. [Medline].
Huang CT, Lin LH. Differentiating roseola infantum with pyuria from urinary tract infection. Pediatr Int. 2013 Apr. 55(2):214-8. [Medline].
Lautenschlager I, Razonable RR. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. Transpl Int. 2012 May. 25(5):493-502. [Medline].
Yoshikawa T, Ohashi M, Miyake F, Fujita A, Usui C, Sugata K, et al. Exanthem subitum-associated encephalitis: nationwide survey in Japan. Pediatr Neurol. 2009 Nov. 41(5):353-8. [Medline].
Yoshikawa T, Asano Y. Central nervous system complications in human herpesvirus-6 infection. Brain Dev. 2000 Aug. 22(5):307-14. [Medline].
Dyer JA. Childhood viral exanthems. Pediatr Ann. 2007 Jan. 36(1):21-9. [Medline].
Tohyama M, Hashimoto K, Yasukawa M, Kimura H, Horikawa T, Nakajima K, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007 Nov. 157(5):934-40. [Medline].
American Academy of Pediatrics. Human herpesvirus 6 (including roseola) and 7. Pickering, LK, ed. Red Book: Report of the Committee on Infectious Diseases. 2003. 357-359.
Asano Y, Yoshikawa T, Suga S, Kobayashi I, Nakashima T, Yazaki T. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics. 1994 Jan. 93(1):104-8. [Medline].
Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. Clin Microbiol Rev. 1997 Jul. 10(3):521-67. [Medline].
Cherry JD. Contemporary infectious exanthems. Clin Infect Dis. 1993 Feb. 16(2):199-205. [Medline].
De Araujo T, Berman B, Weinstein A. Human herpesviruses 6 and 7. Dermatol Clin. 2002 Apr. 20(2):301-6. [Medline].
Dockrell DH. Human herpesvirus 6: molecular biology and clinical features. J Med Microbiol. 2003 Jan. 52(Pt 1):5-18. [Medline].
Drago F, Rebora A. The new herpesviruses: emerging pathogens of dermatological interest. Arch Dermatol. 1999 Jan. 135(1):71-5. [Medline].
Frieden IJ, Resnick SD. Childhood exanthems. Old and new. Pediatr Clin North Am. 1991 Aug. 38(4):859-87. [Medline].
Grossman KL, Rasmussen JE. Recent advances in pediatric infectious diseases and their impact on dermatology. J Am Acad Dermatol. 1991 Mar. 24(3):379-89. [Medline].
Hukin J, Farrell K, MacWilliam LM, Colbourne M, Waida E, Tan R. Case-control study of primary human herpesvirus 6 infection in children with febrile seizures. Pediatrics. 1998 Feb. 101(2):E3. [Medline].
Hurwitz S. Clinical Pediatric Dermatology. 2nd ed. WB Saunders Co; 1993. 35.
Jones CA, Isaacs D. Human herpesvirus-6 infections. Arch Dis Child. 1996 Feb. 74(2):98-100. [Medline].
Leach CT. Human herpesvirus-6 and -7 infections in children: agents of roseola and other syndromes. Curr Opin Pediatr. 2000 Jun. 12(3):269-74. [Medline].
Millichap JG, Millichap JJ. Role of viral infections in the etiology of febrile seizures. Pediatr Neurol. 2006 Sep. 35(3):165-72. [Medline].
Okada K, Ueda K, Kusuhara K, Miyazaki C, Tokugawa K, Hirose M. Exanthema subitum and human herpesvirus 6 infection: clinical observations in fifty-seven cases. Pediatr Infect Dis J. 1993 Mar. 12(3):204-8. [Medline].
Prober C. Sixth disease and the ubiquity of human herpesviruses. N Engl J Med. 2005 Feb 24. 352(8):753-5. [Medline].
Ranger S, Patillaud S, Denis F, Himmich A, Sangare A, M'Boup S. Seroepidemiology of human herpesvirus-6 in pregnant women from different parts of the world. J Med Virol. 1991 Jul. 34(3):194-8. [Medline].
Scott LA, Stone MS. Viral exanthems. Dermatol Online J. 2003 Aug. 9(3):4. [Medline].
Suga S, Yoshikawa T, Asano Y, Yazaki T, Hirata S. Human herpesvirus-6 infection (exanthem subitum) without rash. Pediatrics. 1989 Jun. 83(6):1003-6. [Medline].
Ward KN. The natural history and laboratory diagnosis of human herpesviruses-6 and -7 infections in the immunocompetent. J Clin Virol. 2005 Mar. 32(3):183-93. [Medline].
Ward KN, Andrews NJ, Verity CM, Miller E, Ross EM. Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland. Arch Dis Child. 2005 Jun. 90(6):619-23. [Medline].
Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet. 1988 May 14. 1(8594):1065-7. [Medline].